Nevertheless, low expression of MIR122 is associated with a poor prognosis in patients with NAFLD-associated HCC, providing a new view for discovering new biomarkers and their associated targets and pathways through systematic review and data mining approaches. Here, MIR122 is linked to metabolic dysfunction-associated steatotic liver disease.